Large Cap Biopharmaceutical Companies-Metrics and Valuations…BMY VRTX
Large Cap Biopharmaceutical Companies - Q1 2020 Update The IBB is at $122.69 near the 52 week high but short of 5 year high of $132.53 from Jy '15. FWD PEs of sector are still lower than the market with S&P-500 at 18.9x. Good growth expected. Our Top Picks have done well especially after...
Biotech Reversal Off 2020 Bottom But Within Trading Range: Update-2.. Abbvie (ABBV)
Update-2 2/10...Rally has expanded to mid-caps:ALNY ACAD GWPH ICPT SRPT Etc. ======= Update-1 2/7. 2p ...Abbvie (ABBV) Another one of our top large cap picks ABBV is up 6% o the $92 handle as of mid-day trading on earnings and Allergan acquisition. Full year EPS was $5.28 on GAAP basis on...
Bearish Pattern Emerging for Biotech-Geopolitical News Overwhelms Market…Update-1
Update-1 2/3...3:30p EST... Biopharma stocks firm up after a bad week Large caps are strong with Gilead Sciences (GILD) up over 5% on a story about an experimental antiviral therapy for coronavirus China. GILD is one of the leading antiviral companies for HIV and HCV. Mid-caps in green screen...
New Buy Ideas for 2020: Glaukos Corporation (GKOS)
New Buy Ideas for 2020-Biopharma and MedTech New Buy Idea -Glaukos (GKOS) for ophthalmic disease therapies If you have been reading my recent posts I have been cautious on adding new positions since the JPMorgan Healthcare Conference. After the nice Q4 run-up it would seem prudent to let...
Biotech Sector Watch: Week Ending 1/25/20 After JPMorgan Conference…Update-1/30 sell-off on coronavirus fears
Update-2 1/30 a Mid-day trading- Bearish pattern emerging Many of our indicators have turned bearish: XBI down 1.8% under $90, red screen in mid-caps, large caps at lows for the day, IWM at day lows etc. Fears about coronavirus causing buyers strike? Risk-off, even positive earnings don't...